Journal
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
Volume 20, Issue 1, Pages 105-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.soc.2010.09.001
Keywords
Melanoma; Adjuvant therapy; Interferon; Vaccines; GM-CSF; Ipilimumab
Ask authors/readers for more resources
Adjuvant therapy is commonly used in melanoma because recurrence after surgery usually results in the patient's eventual death. Surgeons have a profound influence on patients' decisions regarding adjuvant therapy, beginning with providing a clear understanding of the risk of specific types of recurrence. This review summarizes the potential oncologic benefits and relevant toxicities of adjuvant systemic therapies for melanoma that are currently available and under investigation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available